Oppenheimer Asset Management Inc. Decreases Position in Haleon plc (NYSE:HLN)

Oppenheimer Asset Management Inc. decreased its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 3.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 739,344 shares of the company's stock after selling 28,258 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Haleon were worth $7,053,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in HLN. Bank of New York Mellon Corp lifted its holdings in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock worth $19,758,000 after buying an additional 475,934 shares in the last quarter. Wrapmanager Inc. purchased a new stake in Haleon in the 4th quarter worth approximately $112,000. Addison Advisors LLC lifted its stake in Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after purchasing an additional 1,106 shares in the last quarter. Holistic Financial Partners boosted its holdings in Haleon by 14.2% in the 4th quarter. Holistic Financial Partners now owns 12,207 shares of the company's stock valued at $116,000 after purchasing an additional 1,518 shares during the period. Finally, Callan Capital LLC grew its position in shares of Haleon by 30.0% during the 4th quarter. Callan Capital LLC now owns 36,266 shares of the company's stock valued at $346,000 after purchasing an additional 8,359 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Price Performance

Shares of Haleon stock traded up $0.10 on Tuesday, hitting $10.68. 7,437,566 shares of the company traded hands, compared to its average volume of 6,454,115. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.81. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $48.33 billion, a P/E ratio of 31.37, a P/E/G ratio of 2.82 and a beta of 0.28. The firm's 50-day simple moving average is $9.61 and its 200 day simple moving average is $9.84.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. This is an increase from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. Haleon's payout ratio is presently 58.97%.

Analyst Ratings Changes

HLN has been the topic of a number of recent analyst reports. Sanford C. Bernstein downgraded Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.